Achieving DSC Certifications With Certified Nurse Specialists

Article

Improving patient care may be possible for institutions achieving Disease-Specific Care certifications with certified nurse specialists at the helm.

According to a presentation at the Oncology Nursing Society’s 46th Annual Congress, improving care for patients with cancer and elevating the role of clinical nurse specialists may be achieved with a Disease-Specific Care (DSC) certification from The Joint Commission.

“Disease-specific care certification focuses [on providing] a framework for continuous, reliable care and gives proof your program meets standards and verifies improvement activity,” said Kathy Burns, MS, APRN-CNS, AGCNS-BC, of The Ohio State’s James Cancer Hospital, which is one of only 3 hospitals in the United States to receive DSC certification for acute leukemia. “Basically, your program is doing what you are saying it’s doing. [It] provides accountability, decreases undesirable variations in care, advances patient outcomes, endorses cultural excellence, [and] provides the community with confidence that the program is providing the quality of care that it is marketing and delivering objectives of the certification [that] are a lasting commitment to clinical excellence for all of us,” Burns said.

Burns is also 1 of more than 72,000 clinical nurse specialists nationwide – a role that she says is vital in the healthcare arena.

“We drive practice change in the organization. [We] advocate to improve patient outcomes and mentor evidence-based practice projects, which I have to say is one of my favorites. We are required to take a course on [evidence-based practices] and then we are required to maintain those competencies. We collaborate on complex patient care issues with multidisciplinary teams throughout the system [and] promote standards on patient care and safety,” she said.

Clinical nurse specialists can also help their institutions achieve a DSC certification by recommending and implementing strategies to improve care and meet disease-specific indicators like:

  • Defining strategies to improve quality
  • Developing policies, procedures, results of tracers, and mock surveys to improve safety
  • Ensuring compliance with clinical practice and evidenced-based care

“Certification programs must demonstrate a systematic approach to care delivery and analysis,” Burns said. “Being at the table, we can help define strategies to improve quality.”

Reference

Burns K, Brown S. Disease Line Clinical Nurse Specialist: The Journey to Obtaining Disease-Specific Care Certification from The Joint Commission. Presented at: The Oncology Nursing Society 46th Annual Congress. April 20, 22, 27, and 29, 2021. Virtual

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content